Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea

MLA

Jaehoon Kim, et al. “Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea.” Rheumatology and Therapy, vol. 8, Jan. 2021, pp. 395–409. EBSCOhost, https://doi.org/10.1007/s40744-021-00278-z.

APA

Jaehoon Kim, Young Joo Kim, Hyun-Jeong Yoo, So-Young Ha, Ju-Young Shin, Min-Young Lee, Mi-Hai Park, Yoon-Bo Shim, Bon-San Koo, & Ja-Young Jeon. (2021). Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea. Rheumatology and Therapy, 8, 395–409. https://doi.org/10.1007/s40744-021-00278-z

Chicago

Jaehoon Kim, Young Joo Kim, Hyun-Jeong Yoo, So-Young Ha, Ju-Young Shin, Min-Young Lee, Mi-Hai Park, Yoon-Bo Shim, Bon-San Koo, and Ja-Young Jeon. 2021. “Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea.” Rheumatology and Therapy 8 (January): 395–409. doi:10.1007/s40744-021-00278-z.